BG
LKFT

Bellevue Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bellevue Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-190
Closed -$23K – 208
2019
Q1 		$23K Buy
+190
New +$19.2K ﹤0.01% 136

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group's LKFT Position: Q1 2021 in Review

Bellevue Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2021, closing a stake of 9,500 shares — an estimated $940K sold.

Bellevue Group first reported a position in LKFT in Q4 2020 and held it in 1 quarter. The position peaked at $940K in Q4 2020. 131 funds tracked by Wall St. Rank hold LKFT as of Q1 2021.

  • Bellevue Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2021 after selling out during the quarter.
  • Bellevue Group sold 9,500 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2021, an estimated $940K.
  • Bellevue Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 1 quarter.
  • Bellevue Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $940K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.